Innovent Biopharmaceutical Transformation
Building on Our Oncology Pipeline with Immuno-Oncology Focus
Increasing Novelty of the mAb and bi-Abs
NDA or Pivotal Stage
CD47 (IBI188)
PoC Stage
CTLA-4 (IBI310)
LAG3 (IBI110)
Phase 1
PD-L1/CD47 (IBI322)
PD-L1/LAG3 (IBI323)
PD-1/Her2 (IBI315)
PI3K8 (IB1376)
ROS1 (IBI344)
RET (selpercatinib)
Approved
PD-1 (TYVYT)
VEGF (BYVASDA)
CD20 (HALPRYZA)
FGFR (Pemazyre)
BCR-ABL (NAILIKE)
VEGFR2 (Cyramza)
Sintilimab
Bevacizumab biosimilar
Rituximab biosimilar
Pemigatinib
Olverembatinib
Ramucirumab
PD-1/TIGIT (IBI321)
TIGIT (IBI939)
PD-1/CD137 (IBI319)
Research Programs
PD-1/IL2 (IBI386)
PD1/IL2v/IL21v (IBI395)
SIRPα (IBI397)
KRAS (IBI351)
......
The fully integrated product development platform to realize
the value as more novel assets enter into clinical trials
Positioning the right molecules for right patients in a
robust, abundant and diversified pipeline
Explore PD-1's value as
a cross-age IO backbone
Innovent
Confidential
Copyright©2022 Innovent
27View entire presentation